NSPR Company Profile and Key Details

NSPR has shown mixed momentum, losing -0.62% over the past week and -30.6% over the past quarter, though year-to-date performance is down -9.55%. Short-term trend indicators are bullishly aligned (SMA20 5.91%, SMA50 3.2%, SMA200 -16.04%). The stock’s 14-day RSI is 59.26 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.03% below its high and over 21.19% above its low. Average 10-day trading volume of 420.63 thousand shares is significantly above the 3-month average of 87.05 thousand, indicating heightened recent market interest.

InspireMD, Inc. generated EPS of -$0.84 over the past year. Five-year average earnings growth is 59.73%. Wall Street analysts project EPS growth of 5.98% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.19. Next year's EPS is expected at $30.15. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 160.87% upside. The low target suggests 160.87% downside. The mean target is $3.00. This offers 160.87% upside. InspireMD, Inc. earnings surprise history is a mixed track record. The quarter that ended May 04, 2026, missed forecasts by -15.79%. The prior quarter beat by -36.36%. Over the last six quarters, Apple has recorded several small beats. These include -5.0% in March 12, 2025.

InspireMD, Inc. has 41.72 million shares outstanding. The public float is 28.85 million shares, elevated short interest at 0.91% of float. This equals 304.03 thousand shares. The short ratio is 3.08 days. Institutional investors hold 52.29% of the float. Insiders own 22.45%. Slosman Marvin holds 2.42 million shares, Holzer Asher has 1.93 million shares and Gleason Shane Thomas has 1.14 million shares. Over the past six months, insider transactions show net selling. They sold 61.19 thousand shares across 10 transactions.

InspireMD, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

InspireMD, Inc. (NASDAQ:NSPR) closed at $1.15 USD, losing -$0.01 (-0.86%) from the previous close of $1.16. The stock is currently mid-range between its 52-week high and low $1.02 and $2.93. With a market capitalization of about $53.93 million, InspireMD, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 235.06 thousand shares, in line with its 52-week average. Headquartered in Miami, None, InspireMD, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Marvin L. Slosman, the company employs approximately 85 people and listed since April 12, 2011. InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.

InspireMD, Inc. trades at a P/E ratio of -2.31, slightly below the S&P 500 average, with a price-to-sales ratio of 5.08 and a price-to-book ratio of 1.98 suggesting the stock is closer to book value. The P/FCF stands at -1.37, also above market averages.

InspireMD, Inc. (NASDAQ:NSPR) shares are flat -9.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows InspireMD, Inc. trading at a premium to the broader market with a P/E of -2.31. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $4.42, suggesting 284.35% upside. Our AI forecast model points to short-term weakness (-15.65% over two weeks), a medium-term fall (-40.87% over three months), and a longer-term gain (266.09% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that InspireMD, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.65%, with price expected at $0.97 by May 22, 2026, within a range of $0.89 to $1.05 3-Month Outlook: Projected fall of -40.87%, reaching $0.68 by August 05, 2026, with a range of $0.62 to $0.74. 1-Year Outlook: Projected gain of 266.09%, with price at $4.21 by May 07, 2027, within a range of $0.24 to $4.68.